Dr. Abbey Presented on Retinal Sustained Drug Delivery Research at Retina World Congress
At the recently held Retina World Congress 2026 meeting, Texas Retina’s Dallas Director of Clinical Research Ashkan M. Abbey, MD, presented on the evolving clinical trial landscape for sustained drug delivery in retinal disease. Dr.
read more
Dr. Ashkan Abbey Presented at the American Academy of Ophthalmology Annual Meeting
Texas Retina’s Ashkan M. Abbey, MD, presented, taught and served as a panelist at AAO 2025, the American Academy of Ophthalmology’s annual meeting held in Orlando, Florida, October 18-20, 2025. Highlights of
read more
Dr. Abbey Discusses How Vorolanib Could Shift the Treatment Approach for Diabetic Macular Edema in New Retinal Physician Article
Texas Retina’s Ashkan M. Abbey, MD, served as a principal site investigator for the Phase II VERONA clinical trial evaluating the efficacy and safety of the vorolanib intravitreal insert (EYP-1901) in diabetic
read more
Dr. Abbey Presented Key Results of DAVIO 2 Clinical Trial for Wet AMD at Retina World Congress
At the recently held 2024 Retina World Congress Meeting, Texas Retina’s Dallas Director of Clinical Research Ashkan M. Abbey, MD, presented topline results from the DAVIO 2 clinical trial investigating EYP-1901 (Duravyu),
read more
Dr. Abbey Presents Phase 1 DAVIO Clinical Trial Results to the Association for Research in Vision and Ophthalmology
Dr. Abbey presented the results from the Phase 1 DAVIO trial at ARVO 2023, the annual meeting of the Association for Research in Vision and Ophthalmology (ARVO). The trial was a first-in-human
read more
Texas Retina Associates First in the Country to Dose a Patient in the DAVIO 2 Clinical Trial
Texas Retina Associates is honored to have randomized the first patient in EyePoint Pharmaceuticals’ Phase 2 “Durasert and Vorolanib in Ophthalmology 2” (DAVIO 2) clinical trial of EYP-1901 for patients with wet macular
read more